Evaluation of therapeutic effect of baricitinib in patients with severe pneumonia requiring non-invasive ventilation induced to Covid 19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220508054780N1

Enrollment

Registered

2022-09-16

Start date

2022-10-02

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute viral infection caused by the corona virus (COVID-19). COVID-19, virus identified

Interventions

Intervention 1: Intervention group: the group of patients with severe pneumonia requiring non-invasive ventilation due to covid-19. this group will be treated with standard covid treatment including r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with severe covid 19 who fullfill PCR or radiological criteria for covid 19 clinical symptoms History of respiratory symptoms from one week before, with a diagnosis of acute respiratory failure Requires non-invasive ventilation to maintain O2 saturation above 85% in ICU

Exclusion criteria

Exclusion criteria: Increased liver enzymes and renal failure Bacterial, fungal and viral infections Bone marrow suppression and decrease in leukocytes

Design outcomes

Primary

Measure	Time frame
The mortality rate of patients with acute respiratory infection of the coronavirus who admitted in ICU. Timepoint: 30, 60 and 90 days. Method of measurement: observation of the number of dead patients.;Score of disease severity questionnaire (APACHEII). Timepoint: 30, 60 and 90 days. Method of measurement: APACHEII questionnaire.;Number of days that a patient is on ventilator. Timepoint: 30, 60 and 90 days. Method of measurement: observation of the number of days the patient is on ventilator.;Incidence of sepsis. Timepoint: 30, 60 and 90 days. Method of measurement: Evaluation of the patient's clinical symptoms and laboratory findings.;Incidence of respiratory distress. Timepoint: 30, 60 and 90 days. Method of measurement: Clinical evaluation of respiratory distress in patients.	—

Measure

Time frame

The mortality rate of patients with acute respiratory infection of the coronavirus who admitted in ICU. Timepoint: 30, 60 and 90 days. Method of measurement: observation of the number of dead patients.;Score of disease severity questionnaire (APACHEII). Timepoint: 30, 60 and 90 days. Method of measurement: APACHEII questionnaire.;Number of days that a patient is on ventilator. Timepoint: 30, 60 and 90 days. Method of measurement: observation of the number of days the patient is on ventilator.;Incidence of sepsis. Timepoint: 30, 60 and 90 days. Method of measurement: Evaluation of the patient's clinical symptoms and laboratory findings.;Incidence of respiratory distress. Timepoint: 30, 60 and 90 days. Method of measurement: Clinical evaluation of respiratory distress in patients.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBenyamin Fazli

Mashhad University of Medical Sciences

fazlib@mums.ac.ir+98 51 3840 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026